TMS for Treatment-Refractory Tourette Syndrome
Repetitive transcranial magnetic stimulation (rTMS) can be considered as an adjunctive treatment option for severe, treatment-refractory Tourette syndrome, though the evidence remains limited and less robust than for deep brain stimulation.
Current Evidence Base
The most recent systematic review and meta-analysis 1 from 2025 provides important context: when analyzing only randomized controlled trials, rTMS showed a statistically insignificant decrease in tic severity (YGTSS scores: MD = -5.01, P = 0.090). However, when combining RCTs with non-randomized trials, rTMS demonstrated significant improvement (MD = -11.6, P < 0.001). This discrepancy highlights the weakness of the current evidence base.
Key Considerations for Clinical Decision-Making
When to Consider rTMS:
- Severe tics causing physical discomfort, pain, or injury
- Failed first-line treatments: inadequate response to behavioral therapy (CBIT) and at least two standard pharmacological agents (alpha-2 agonists, dopamine antagonists)
- Patient preference for less invasive intervention before considering deep brain stimulation
- Comorbid OCD: rTMS showed more consistent benefit for obsessive-compulsive symptoms (MD = -6.6, P = 0.010) 1
Protocol Specifications:
The most studied approach targets the supplementary motor area (SMA) bilaterally with:
- Low-frequency stimulation (1 Hz)
- 20 sessions over 4-6 weeks
- fMRI-guided targeting when available 2
Critical Limitations
The evidence quality is problematic 3. Most studies are small case series or open-label trials. Only three controlled studies exist, and publication bias likely favors positive results 4. The 2022 systematic review 3 emphasizes that while results "tentatively suggest" benefit, the lack of large-scale sham-controlled studies severely limits confidence in these findings.
Comparative Effectiveness
Deep brain stimulation demonstrates superior efficacy for treatment-refractory TS. DBS showed significant improvement in RCTs (YGTSS: MD = -14.71, P < 0.001) 1 with approximately 97% of published cases showing substantial tic improvement [@1-7@]. However, DBS is invasive, requiring neurosurgery with inherent risks.
Practical Algorithm
- Confirm treatment resistance: Document failed trials of behavioral therapy plus ≥2 pharmacological agents
- Assess severity: Tics must cause significant functional impairment, not just be present
- Screen for contraindications: Seizure history, metallic implants, pregnancy
- Trial rTMS before DBS: Given its non-invasive nature, despite weaker evidence
- Monitor response: Use validated scales (YGTSS) at baseline, mid-treatment, and post-treatment
- Consider DBS referral: If rTMS fails after adequate trial (20+ sessions)
Important Caveats
- Durability unknown: Most studies lack long-term follow-up beyond 3 months 5
- Optimal parameters uncertain: Target location, frequency, and session number remain under investigation 3
- Not FDA-approved for Tourette syndrome
- Insurance coverage may be limited or unavailable
- Comorbidities matter: Patients with TS-OCD may respond better than those with pure TS 5
The evidence suggests rTMS may provide modest benefit as a bridge therapy between standard treatments and invasive neurosurgery, but clinicians should set realistic expectations given the limited and inconsistent evidence base.